Self-reported smell and taste recovery in COVID-19 patients: a one-year prospective study

Introduction

One year after the outbreak of the coronavirus-19 disease (COVID-19) pandemic in Europe, alterations in smell and taste have unquestionably emerged as a highly prevalent symptom and the most reliable predictor of the severe acute respiratory syndrome–coronavirus-2 (SARS-CoV-2) infection [1–3]. In addition, a high persistent rate of chemosensory disorders has been reported 6 months after onset [4,5]. However, the results of these reports cannot be considered as definitive as in some forms of post-viral anosmia, recovery times of more than one year have been reported in the past [6].

Although psychophysical evaluation of the olfactory function has been observed to have higher sensitivity, especially in detecting mild hyposmia [4,7], the self-reported evaluation of chemosensitivity has a baseline parameter of comparison consisting in the subjective perception of smell or taste preceding the onset of COVID-19. In older adults, indeed, the prevalence of psychophysical olfactory impairment in the setting of no reported deficit is 15% [8].

The aim of the present study was to estimate the one-year prevalence and recovery rate of self-reported chemosensory dysfunction in a series of subjects with previous mild-to-moderate symptomatic COVID-19.

Materials and Methods

The study was approved by the Ethics Committee of the Friuli Venezia Giulia Region (CEUR-2020-Os-156), and informed consent was obtained verbally for telephone interviews.

Results

Of 315 patients completing the survey at baseline, 47 did not answer or refused the follow-up interview, thus leaving 268 responders (85.1%). Baseline socio-demographic and clinical characteristics of 268 patients are reported in Table 1. The median age of the study cohort was 48 years (interquartile range, 38-56 years). There was a female preponderance with 166 out of 268 being females (61.9%). Associated co-morbidities were reported by 91 cases (34.0%) with the most common being obesity reported by 32 patients (11.9%) followed by cardiovascular diseases (n=25, 9.3%) and immunosuppression (n=19, 7.1%).

The median time to achieving a negative swab was 22 days (interquartile range, 15-31 days). Overall, 187 of 268 responders (69.8%, CI 95% 63.9-75.2) reported an altered sense of smell or taste at baseline (SNOT-22 > 0) with 99 (36.9%, CI 95% 31.1-43.0) reporting the highest SNOT-22 score, for severe problem. Particularly, 152 subjects (81.3%) self-reported combined chemosensory dysfunction, 19 (10.2%) patients self-reported isolated smell impairment and 16 patients (8.6%) self-reported isolated taste disorder. No sociodemographic characteristic or clinical feature was associated with either chemosensory dysfunctions or its severity at baseline (data not shown).

After 12 months, 57 patients (21.3%; 95% CI: 16.5-26.7%) still reported chemosensory dysfunction, with 34 subjects still reporting both smell and taste dysfunction, 15 reporting smell impairment and 5 taste disorder. Among patients with persistent chemosensory dysfunction, only 4 (7.0%) complained blocked nose. Among the 187 patients who have complained a COVID-19 associated chemosensory dysfunction at baseline, 130 (69.5%; 95% CI 62.4-76.0%) reported complete resolution of smell or taste impairment, 41 (21.9%; 95% CI: 16.2-28.5%) reported a decrease in the severity, and 16 (8.6%; 95% CI: 5.0-13.5%) reported the symptom was unchanged or worse (Table 2). Baseline socio-demographic and lifestyle factors were not associated with the persistence of chemosensory dysfunction (Table 3). After adjustment for covariates, the severity of chemosensory dysfunction at baseline (OR=3.32; 95% CI: 1.32-8.36 for SNOT-22 score ≥ 4) and a longer time to achieving a negative swab (OR=2.18; 95% CI: 1.12-4.27) were associated with a higher risk of persistence of symptoms at 12-months.

Discussion

Among the 187 patients who have complained a COVID-19 associated chemosensory dysfunction, 69.5% experienced a complete resolution of these symptoms at 12-months while 30.5% still reported impairment in their chemosensory function. Thus, the 12-months overall prevalence of persistent altered sense of smell or taste in this series of subjects with previous mild-to-moderate symptomatic COVID-19 was 21.3%.

To the best of our knowledge this is the first study to estimate the 12-months prevalence and recovery rate of self-reported chemosensory dysfunction in a series of subjects with previous mild-to-moderate symptomatic SARS-CoV-2 infection. Such a long follow-up is essential to estimate the real prevalence of COVID-19 related chemosensory disorders as functional recoveries after one year from infection with other viruses have been reported in the past even [6].

The data from our study highlights a significant rate of lasting olfactory dysfunction as a legacy of the pandemic. Considering the spread out of SARS-CoV-2 infections in Europe with more than 36,000,000 cases to date [11], the burden of chemosensory disorders on the health systems will be even more pressing. Indeed, given that our estimates are based on self-reported symptoms, these patients will likely seek medical care for their chemosensory disorders.

This prevalence is likely underestimated compared to the rate that would have been obtained using the most accurate psychophysical evaluation [4,12]. However, this subjective evaluation may be more accurate in estimating the percentage of patients in whom the smell or taste disturbance has repercussions on their quality of life. Furthermore, the evaluation with psychophysical tests alone could overestimate the prevalence of residual COVID-19 related chemosensory disorders including all those subjects who were unaware of having a previous olfactory or gustatory dysfunction [8].

These observations should prompt the experts in chemosensory disorders to make further efforts to test possible treatments for post-COVID-19 smell and taste disorders. Current therapies are essentially based on the experience gained in the study of other forms of post-viral anosmia. Recently, the Clinical Olfactory Working Group members made an overwhelming recommendation for olfactory training for post-viral anosmia including COVID-19 [13]. However, it is imperative to design multicentre clinical trials to test olfactory training efficacy as well as new therapeutic strategies for improving chemosensory outcomes in patients with post-COVID-19 chemosensory disorders. The high number of potentially recruitable patients offers a unique opportunity to test the efficacy of new therapeutic approaches for post-viral chemosensory disorders.

We found that the severity of chemosensory dysfunction at baseline was associated with a higher risk of persistence of symptoms at 12-months. Thus, patients with more severe smell or taste impairment should be preferentially included in randomized clinical trials evaluation the efficacy of different treatment approaches, and research is required to determine of treatment at an early stage can reduce the rate of persistent dysfunction.

We also found that a longer duration of viral persistence on PCR testing was associated with an increased risk of persistent chemosensory dysfunction. It has been shown that SARS-CoV-2 gains entry to the supporting ells of the respiratory epithelium [14]. It could be hypothesized that persistence of viral infection in the nose prevents recovery of the supporting cells, which leads indirectly to injury of the olfactory sensory neurones and persistent loss. In contrast, rapid viral clearance may allow repair of the integrity of the olfactory epithelium before loss of the olfactory sensory neurons occurs.

The data form the present study should be taken cautiously owing to several study limitations. Symptoms were self-reported, based on cross-sectional surveys, and may therefore contain suboptimal sensitivity. Subjective evaluation of the olfactory function was observed, indeed, to be inadequate to fully evaluate olfactory recovery with several authors having underlined that subjectivity of self-reporting may lead to underestimation of the prevalence of olfactory dysfunction. It is clear that patients’ rating of whether smell and or taste are impacted differentially is very difficult to interpret, due to impact of loss perception of flavour through retronasal olfaction, and little can be inferred from this aspect of the study. Moreover, the study cohort was relatively small and patients with more severe COVID-19 were excluded.

In conclusion, a substantial proportion of patients with previous mild-to-moderate symptomatic COVID-19 characterized by new onset of chemosensory dysfunction still complained on altered sense of smell or taste one-year after the onset. As recovery from post-viral loss may continue beyond this period [6,15], further assessments will be necessary to conclude whether smell and taste dysfunction is permanent. Moreover, there is urgent need for more efforts and research on treatment strategies for post-COVID-19 chemosensory dysfunction.